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Intravenous fluid administration in veterinary patients can alter coagulation function
by several mechanisms. Both crystalloid and colloid fluids cause hemodilution,
reducing platelet count and plasma coagulation protein concentrations. Hemodilution
is associated with a hypercoagulable effect at low dilutions and a hypocoagulable
effect at higher dilutions. Composition of crystalloid fluids likely has a minor effect,
primarily dependent on fluid ion composition. Hypertonic crystalloids may also cause
hypocoagulability. Colloids, both synthetic and natural, can cause hypocoagulability by
several mechanisms beyond the effects of hemodilution. These include impaired platelet
function, decreased plasma coagulation factor activity, impaired fibrin formation and
crosslinking, and accelerated fibrinolysis. The vast majority of the veterinary literature
investigates the hypocoagulable effects of hydroxyethyl starch–containing fluids using in
vitro, experimental, and clinical studies. However, results are inconsistent, likely due to
the varying doses and physicochemical properties of the specific fluid products across
studies. In addition, some evidence exists for hypocoagulable effects of gelatin and
albumin solutions. There is also evidence that these colloids increase the risk of clinical
bleeding in people. Limitations of the veterinary evidence for the hypocoagulable effects
of colloid fluids include a predominance of in vitro studies and in vivo studies using
healthy subjects, which exclude the interaction of the effects of illness. Therefore, clinical
relevance of these effects, especially for low-molecular-weight hydroxyethyl starch, is
unknown. Firm recommendations about the most appropriate fluid to use in clinical
scenarios cannot be made, although it is prudent to limit the dose of synthetic colloid
in at-risk patients. Clinicians should closely monitor relevant coagulation assays and for
evidence of hemorrhage in at-risk patients receiving any type of fluid therapy, especially
in large volumes.
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INTRODUCTION
Intravenous (IV) administration of crystalloid and colloid fluids can affect coagulation function
by hemodilution, as well as through factors related to the composition of the fluid (Box 1).
The mechanisms are multifactorial, affecting platelet function, coagulation factor concentration,
and clot strength, and vary between fluid types. The majority of the literature pertaining to
Boyd et al. Intravenous Fluids and Coagulation




◦ Hypercoagulability at low dilutions, possibly due to reduced
antithrombin activity
◦ Hypocoagulability at higher dilutions, due to reductions in platelet
number and plasma coagulation factor concentration
Colloids (synthetic and natural)
• Impaired platelet function
◦ Reduced expression/accessibility of fibrinogen receptor integrin
αIIbβ3
◦ Non-specific binding to the platelet surface
◦ Acquired type 1 von Willebrand disease
• Decreased plasma coagulation factor activity
◦ Specific decrease in factor VIII
◦ Non-specific decrease in all factors
• Impaired fibrin formation and crosslinking
◦ Qualitative differences in fibrin clot
◦ Inhibition of factor XIII interaction with fibrin
◦ Inhibition of thrombin interaction with fibrinogen
• Accelerated fibrinolysis
◦ Enhanced conversion of plasminogen to plasmin
◦ Reduced inhibition of plasmin by α2-antiplasmin
veterinary medicine includes in vitro studies, using blood from
healthy animals, and in vivo studies, administering fluids of
concern intravenously to healthy animals. Some studies have also
examined effects of fluids on coagulation in experimental animal
models of disease, as well as in clinical patients. These study
designs each have advantages and limitations. In vitro or healthy
animal studies are better able to elucidate subtle mechanistic
interactions with coagulation, without the confounding effects
of illness. However, their clinical relevance may be difficult to
interpret. The downside of utilizing disease models or clinical
patients is that subtle differences in coagulation are often not
detected without large sample sizes because of variability caused
by the illness itself or other aspects of clinical management.
The authors have endeavored to provide a broad survey of the
available data regarding the effects of fluids on coagulation in
companion animals. The reader is encouraged to evaluate the
Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial
thromboplastin time; AT, antithrombin; BMBT, buccal mucosal bleeding
time; CFT, clot formation time (in the ROTEM assay); CT, clotting time (in the
ROTEM assay); FVIII, coagulation factor VIII; HES, hydroxyethyl starch; LRS,
lactated Ringer solution; MA, maximum amplitude (in the TEG assay); MCF,
maximum clot firmness (in the ROTEM assay); MW, molecular weight; PCT,
platelet closure time (as measured by the PFA-100); PFA-100, platelet function
analyzer; PT, prothrombin time; ROTEM, rotational thromboelastometer; TEG,
thromboelastograph; vWF, von Willebrand factor.
breadth of the evidence presented herein and to choose the most
relevant data for their specific patients.
HEMODILUTION
The dilutional effects of fluid administration on the coagulation
system are proportionate to the degree of hemodilution. The
effects include decreasing platelet number, but not function, and
decreasing procoagulant and anticoagulant [e.g., antithrombin
(AT)] proteins to varying degrees (1). The effect of hemodilution
is often not the sole purpose of studies assessing coagulation;
however, it is often accounted for by the addition of a
control group that receives isotonic crystalloid fluid only, or
blood diluted with crystalloid only. Therefore, the effects of
hemodilution can be surmised by assessing before-and-after
changes in control groups within these studies. This evidence on
the effects of hemodilution is discussed in detail in the following
section on crystalloid fluids.
When comparing the effects on coagulation between fluid
types, there are some important considerations concerning
hemodilution and the relevant pharmacodynamics of the fluids.
It can be challenging to validate the degree of hemodilution
between groups in in vivo studies. There are a range ofmethods to
measure degree of hemodilution, including utilizing the dilution
of endogenous (e.g., hemoglobin, albumin) or exogenous (e.g.,
indocyanine green) markers, none of which are perfect (2,
3). Thus, the exact degree of hemodilution, or blood volume
expansion, caused by different fluid types can vary between
studies. However, there is strong evidence that themagnitude and
duration of blood volume expansion following administration of
synthetic colloid are greater than those of an equal volume of
isotonic crystalloid. This may be context-sensitive and dependent
on the integrity of the endothelial surface layer, although this
relationship is not fully understood (4–7). Studies in healthy
dogs (8) and people (9) demonstrated 3- to 4-fold greater
hemodilution for dextran, hydroxyethyl starch (HES), and gelatin
colloids than isotonic crystalloid. However, the subjects were
euvolemic prior to fluid administration, and the fluid doses
exceeded common clinical practice. Colloids also had a greater
volume effect than crystalloids in healthy dog and pig models
of non-traumatic hemorrhagic shock, after fluid redistribution
(10–12). Conversely, in an experimental model of orthopedic
surgery, dogs administered 10 mL/kg of either high-molecular-
weight (MW) HES or balanced isotonic crystalloid showed a
similar drop in packed cell volume 1 h postinfusion (13). Clinical
trials in critically ill hypovolemic people (14–18) and dogs
(19) show that blinded clinicians targeting self-defined clinical
endpoints administer on average 1 to 1.5 times the volume
of isotonic crystalloid compared to HES, much less than the
3- to 4-fold difference predicted by experimental studies. The
targeted endpoints could include normalization of mean arterial
blood pressure, heart rate, blood lactate concentration, or central
venous pressure, among other clinician-specific criteria. While
this may indicate lack of a beneficial colloid osmotic effect in
critical illness, it is important to note that the degree of blood
volume expansion was not measured in these trials. The volume
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of fluid administered may simply reflect usual clinical practice.
While these uncertainties make it difficult to exactly apportion
hypocoagulability following fluid administration into dilutional
and non-dilutional components, it is the overall effect that is
clinically relevant.
CRYSTALLOIDS
The evaluation of in vitro crystalloid effects on coagulation has
been primarily focused on isotonic crystalloids, although some
studies have also evaluated hypertonic solutions. The effect of
crystalloids on coagulation is thought to be primarily dilutional;
however, variability in the ionic and buffer composition of the
fluids may be relevant, specifically with regard to calcium ion
content and fluid pH. Most in vitro studies have been designed
to evaluate the putative effect of a bolus of different amounts of
crystalloid, in ratios varying from 4 to 20% of crystalloid to blood,
to mimic clinically relevant infusion volumes. Overall, the effects
on coagulation appear proportionate to the degree of dilution,
with measurable effects generally occurring beyond 20% dilution,
or one part fluid to four parts blood.
Saline 0.9%
Saline 0.9% has been extensively studied because of its use as a
diluent for many HES and dextran formulations. In most studies,
the dilutional effect on platelet count is not addressed, although
it may decrease with increasing dilutions. This may result in
some of the recorded changes, especially in platelet dependent
assays (e.g., aggregometry). In humans, a 40% in vitro dilution
of whole blood with 0.9% saline results in decreased platelet
function as measured by the Impact cone and plate analyzer
(20). Using the platelet function analyzer 100 (PFA-100), in
vitro 10, 20, 30, and 40% dilutions of human whole blood with
0.9% saline demonstrated a dilution-dependent prolongation of
the platelet closure time (PCT) (21, 22). Despite these changes,
whole-blood (impedance) platelet aggregometry using adenosine
diphosphate (ADP) or collagen as agonists was unaffected by
a 5%, 10%, 15%, or 20% in vitro dilution with 0.9% saline
(22, 23). Platelet aggregometry (impedance or optical) is a low-
shear test for platelet function, whereas the PFA-100 uses high-
shear conditions. Platelet responses to agonists vary between
shear conditions, and platelets under high-shear conditions are
reliant on von Willebrand factor (vWF) for adhesion (24).
Differences in shear velocities are relevant because they may
be representative of platelet performance under venous (low-
shear) or arterial (high-shear) conditions. Similar results were
seen using optical aggregometry, where aggregation to ADP and
collagen was unchanged from baseline at 10% and 20% dilution,
but was impaired at 40% (25). It is unclear if platelet count was
standardized across dilutions in this study; therefore, absolute
platelet count may have affected results. The impairment in this
case was not different from that seen with 40% dilution with
6% low MW HES, making it difficult to distinguish between
dilutional and functional impairment. In a different assessment
of platelet function, the in vitro addition of 0.9% saline to human
whole blood in dilutions ranging from 2.5 to 30% did not affect
platelet P-selectin expression or fibrinogen binding following
ADP stimulation (26).
Several in vitro studies in dogs have not detected an effect
of 0.9% saline on PCT using ADP/collagen cartridges at 10%
dilution but have identified mild prolongation at 20% dilution
(27–30). One of these studies documented platelet count for
each dilution, reflecting that some samples at 20% dilution had a
platelet count below the manufacturer’s recommendedminimum
for assessment of platelet function (29). Therefore, the mild
prolongation in PCT is likely due to dilution of platelets.
Viscoelastic coagulation evaluation of in vitro 0.9% saline
dilution of whole blood demonstrated changes consistent with
hypercoagulability in some human studies, although it is unclear
if this is an artifact or should be a clinical concern. Using
thromboelastography (TEG), Roche et al. described slightly
increased clot strength and increased rate of clot formation when
whole blood was diluted with 0.9% saline at 20% to 40% dilutions
(31). At a 60% dilution, the TEG indicated hypocoagulability
(31). Other studies have identified decreases in clot strength
with a 40% in vitro dilution (20, 25). Overall, minimal change
in coagulation status occurs at in vitro 0.9% saline dilutions
<20% (23). Using another viscoelastic measurement (Sonoclot),
no changes in clot rate or strength were seen following addition of
0.9% saline to whole blood at 20% or 40% dilutions (32, 33). The
slight increase in coagulability with modest hemodilution with
0.9% saline may be due to diluted AT, allowing faster thrombin
formation, or may be an artifact. The overall clinical relevance
is uncertain. In rotational thromboelastometry (ROTEM) studies
of in vitro 0.9% saline dilution of whole blood, impaired platelet
function appears to play less of a role than fibrinogen in the
decreased clot firmness (34–36). This is inferred from greater
effects seen on the FibTEM test, where platelet function is
excluded, than comparable effects on baseline tests.
In dogs, in vitro addition of 0.9% saline to whole blood at a
20% dilution appeared to cause relative hypocoagulability using
the ExTEM test, which is a tissue factor–initiated ROTEM test
(statistical significance not noted) (27). This was characterized
by prolonged time to initiate clotting, decreased speed of clot
formation, and lower clot strength. However, another study using
10 and 20% dilutions of canine whole blood failed to document
significant changes using ROTEM (37).
In vivo, a 10 mL/kg IV infusion of 0.9% saline given to
healthy people failed to prolong PCT (collagen/epinephrine and
collagen/ADP cartridges), change TEG parameters, or alter flow
cytometric assessment of platelet fibrinogen binding or P-selectin
expression following activation by ADP or thrombin receptor–
activating peptide (21, 38). Another study that administered
1 L of 0.9% saline IV to healthy volunteers demonstrated
hypercoagulability on TEG, including shortened R time with
increased angle and maximum amplitude (MA) (39). This
equates to ∼15 mL/kg, resulting in a 9% decrease in hematocrit.
This same study documented decreases in fibrinogen and AT
concentrations, and the authors hypothesized that the decreased
AT may have caused the observed hypercoagulability. A further
study by this group, whereby healthy people received 14 mL/kg
of a 0.9% saline bolus, showed that the induced hypercoagulable
effect was transient, dissipating as the bolus was redistributed
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(40). Using optical aggregometry, Ruttmann et al. also noted
a slightly increased aggregation response to high-dose (100
µmol/L) ADP and to ristocetin (1.2mg/mL) in humans following
a 1 L IV bolus of 0.9% saline (39).
In healthy dogs, a 20 mL/kg IV bolus of 0.9% saline given
over an hour resulted in no change in the PCT, which remained
within the reference range (41). A hemorrhagic shock study in
greyhound dogs compared 80 mL/kg of 0.9% saline to 20 mL/kg
of low MW HES administered IV after removal of 48 mL/kg of
blood (42). It showed mild prolongation of PCT in both groups,
consistent with dilution; however, a slightly greater magnitude
of change was observed in dogs that received 0.9% saline. In
healthy ponies, an IV infusion of 80 mL/kg of 0.9% saline
given over 2 h did not result in changes in cutaneous bleeding
time, vWF antigen activity, prothrombin time (PT), or activated
partial thromboplastin time (aPTT) (43). Another study of a 10
mL/kg IV bolus of 0.9% saline given to adult horses showed a
transient prolongation of PT and aPTT 1 h after the completion
of the bolus (44). Additionally, a transient decrease in factor VIII
(FVIII) activity was seen in these horses, although there was no
change in vWF activity as a result of the bolus (44). Following this
bolus, mild transient hypocoagulability was demonstrated using
viscoelastic assessment, but platelet function as measured by PFA
and optical aggregometry was unaffected (44).
Polyionic and Ringer Solutions
With regard to hemostasis, the composition of crystalloid
(polyionic vs. saline) may result in differential effects, although
the magnitude of these effects may not be clinically relevant. One
meta-analysis of the human literature suggested that the use of
0.9% saline was associated with greater blood loss compared to
lactated Ringer solution (LRS) when used in high-risk patients
(45). Proposed mechanisms included the presence of calcium
ions in LRS or the effect on coagulation of a saline-induced
hyperchloremic acidosis.
Similar to 0.9% saline, the in vitro addition of LRS to human
whole blood in dilutions ranging from 2.5 to 30% did not affect
the expression of P-selectin or fibrinogen binding following ADP
stimulation (26). Serial dilutions of human whole blood with LRS
did result in significant increases in the rate of clot formation
(TEG angle), most prominent at the 30 to 50% dilutions and
progressing to hypocoagulability above a 50% dilution (31, 46). In
another report, a 33% dilution of human whole blood with LRS
did not change the Sonoclot signature from baseline; however,
at a 66% dilution, the signature indicated hypocoagulability
(32). These changes were corroborated using ROTEM and
TEG analysis as well, with significant thrombocytopenia and
hypocoagulability following in vitro dilution of human whole
blood with LRS (47). The hypocoagulable effect of LRS on
viscoelastic testing could be ameliorated by correcting the platelet
count in the diluted sample (48). Another report evaluating
the viscoelastic coagulation monitoring (ROTEM and Sonoclot)
effects of in vitro dilutions of human whole blood with LRS did
not show significant differences (49).
In cats, a 14% dilution of whole blood with Ringer acetate
resulted in ROTEM hypocoagulability, as seen by prolongations
in clotting time (CT; InTEM assay) and clot formation time (CFT;
ExTEM and InTEM assays), and reducedmaximum clot firmness
(MCF; ExTEM, InTEM, and FibTEM assays) and alpha (ExTEM
and InTEM assays) (50). Dose-dependent hypocoagulabilty
was demonstrated on TEG analysis with addition of LRS to
canine whole blood (16%, 33%, and 66% dilution), showing
progressively decreasing angle and MA starting from either 16%
dilution or 33% dilution, respectively (51).
In vivo studies conducted in healthy individuals have shown
mixed results in regard to the effects of administered polyionic
solutions; however, most lean toward mild hypocoagulability.
A 10 mL/kg IV bolus of LRS given to healthy people failed to
prolong PCT using either ADP/collagen or epinephrine/collagen
cartridges, compared to baseline (52). In dogs administered
a 15 mL/kg IV bolus of modified acetate-containing Ringer
solution, no change in PCT or ROTEM values was seen,
compared to baseline (53). In the context of experimental severe
hemorrhage, dogs resuscitated with LRS (total of 50 mL/kg
IV) and stored whole blood (in equal volume to shed blood)
showed little alteration in measured PT and aPTT, but appeared
to have decreases in activity of factors II, V, VII, VIII, and X,
compared to baseline (statistics not shown) (54). In healthy dogs
anesthetized for orthopedic surgery that received an IV bolus of
10 mL/kg LRS, PT, aPTT, FVIII:C, and vWF:Ag did not change
significantly when measured 1 h after the bolus (13). A mild
prolongation of buccal mucosal bleeding time (BMBT) was seen
in these dogs, accompanied by a transient decrease in platelet
count, but without effects on platelet aggregation in response to
platelet activating factor. In rabbits, hemodilution achieved by
replacement of 40% of estimated blood volume with five times
that volume of LRS resulted in hypocoagulability in both TEG
and traditional coagulation testing (55). In this study, it appeared
that procoagulant coagulation factors were decreased in excess of
anticoagulant factors (e.g., AT, protein C) (55).
Despite the paucity of clinical veterinary studies to draw upon
in this area, one observational study in dogs with parvoviral
enteritis compared TEG changes in dogs that received bolus fluid
therapy (median, 26.5 mL/kg) to those that received a smaller
amount (median, 10 mL/kg) (56). Dogs that received bolus
therapy showed relative hypercoagulability, but also likely had
more severe disease. Resuscitation corresponded with a lower
median HCT and higher platelet concentration from admission
values for both groups, with a decreased AT activity in the
group that received a larger volume of LRS. In both groups,
the fibrinogen concentration was above the assay detection limit
(700 mg/dL), raising the question of the role of fibrinogen in
maintaining ex vivo coagulation competency in animals with
severe inflammation that are aggressively resuscitated (56).
Hypertonic Crystalloid
The effects of hypertonic saline on coagulation have been assessed
in a limited number of reports. In vitro addition of 7.2% saline to
canine whole blood prolonged PCT (ADP/collagen cartridge) at
both 4% and 10% dilutions, compared to undiluted blood (27).
In this study, hypocoagulability was seen in ROTEM analysis,
specifically in prolongation of the ExTEM CFT and decrease in
MCF. Similar findings were seen when 3% saline was added to
canine whole blood at an 11% dilution, with prolonged PCT,
Frontiers in Veterinary Science | www.frontiersin.org 4 April 2021 | Volume 8 | Article 662504
Boyd et al. Intravenous Fluids and Coagulation
increased ExTEM CT and CFT, and reduced ExTEM MCF (57).
In dogs with intracranial hypertension given 4 mL/kg of 7.2%
saline over 5min, no significant change in PCT was detected,
despite the median PCT being outside of the reference interval
immediately after the bolus and 1 h later (58). The only change in
ROTEM analysis of these patients was a slightly shortened CT in
the FibTEM assay, which is likely not clinically relevant, and was
not seen in the prior in vitro study (57). In another study where
healthy dogs were given 5 mL/kg of 7.5% saline IV at a rate of 1
mL/kg per minute, no change was detected in TEG parameters
up to 3 h after the end of the infusion (59).
Overall, the effects of administration of large volumes
of crystalloid can cause hypocoagulability, primarily through
dilutional effects, and without clear distinction between fluid
types. Caution should be used in animals receiving large amounts
(>40 mL/kg) of crystalloid, especially in those at increased
risk of bleeding. A balanced resuscitation protocol with fresh
frozen plasma to maintain concentrations and activity of the key
coagulation factors should be considered in patients at increased
risk of bleeding (1) with the overall context of the patient
kept in mind. Despite these recommendations, the effect of
crystalloid on coagulation tests may be transient, considering its
redistribution to the extravascular space, and may not necessarily
result in clinically relevant hemorrhage, depending on individual
patient comorbidities.
COLLOIDS
Synthetic colloid-containing fluids are commonly administered
for fluid resuscitation in small animals (60) and horses (61).
They are favored by some veterinarians for their potential to
maintain intravascular colloid osmotic pressure and expand
blood volume more effectively for a given infused volume than
isotonic crystalloids (8, 43, 62). However, they have the potential
to cause hypocoagulability through dilutional and non-dilutional
mechanisms, including direct effects on platelets and coagulation
factors. Along with other adverse effects, the documented
clinical relevance of colloid-induced hypocoagulability has led
to decreased use of synthetic colloids for fluid resuscitation in
human critical care (63). While similar hypocoagulability has
been demonstrated in veterinary species, the clinical relevance
is unclear at this time. This section will broadly review the
mechanistic data for the coagulation effects of synthetic colloids
and then detail evidence concerning HES and gelatin separately.
Lastly, a brief review of the effects of exogenous albumin
administration will be provided.
Mechanisms of Hypocoagulability
Synthetic colloids cause a dilutional coagulopathy proportionate
to the degree of blood volume expansion, which may be of
greater magnitude than that from the same infused volume of
isotonic crystalloid. There are several additional mechanisms by
which synthetic colloids may lead to impairment of coagulation.
These include intrinsic platelet dysfunction, acquired von
Willebrand disease, a specific decrease in FVIII activity, non-
specific decreases in all coagulation factor activity, impaired
fibrin formation and crosslinking, and accelerated fibrinolysis.
Reduced cell surface expression, or reduced accessibility for
ligand binding, of the activated fibrinogen receptor integrin
αIIbβ3 (previously known as glycoprotein IIb–IIIa) has been
demonstrated by flow cytometry of human platelets. This
includes samples collected from patients undergoing elective
surgery treated with HES of varying MW (21, 38) or platelets
treated with HES or gelatin in vitro (21, 38, 64). Effects of gelatin
on this fibrinogen-binding receptor may depend on the type of
gelatin tested; reduced, increased, and no effect on expression
have all been reported (see below for further discussion on the
effect of calcium in diluent) (64). Binding of HES to the platelet
surface has also been demonstrated by flow cytometry of human
platelets treated with abciximab, a monoclonal antibody that
blocks HES binding to integrin αIIbβ3 (65). This is often viewed as
non-specific coating of platelets by HES, although the molecular
basis is not fully understood. Platelet adhesion may also be
impaired because of reduction of the activity of vWF (43, 44, 66–
71). A study of human patients administered HES demonstrated
an equal decrease in all vWF multimers, characterizing this as
acquired type 1 von Willebrand disease (72). Gelatin interferes
with collagen binding of vWF, not the absolute concentration;
therefore, it may form a complex with the coagulation factor,
prompting its excretion (66).
Functional platelet studies have demonstrated a reduction in
platelet adhesion and activation, as evidenced by prolonged PCT
(21, 38), although not all studies consistently show this effect.
Although gelatin interferes with ristocetin-induced aggregation
(66, 67, 73–75), it mostly fails to impair aggregation stimulated
by other agonists (66, 76–80). The effect of gelatin on PCT is also
mixed between species (64, 81).
Given the close association between vWF and FVIII, which
circulate as a bound complex, it is unsurprising that synthetic
colloids also cause a reduction in the activity of FVIII (67–
69, 72, 74, 82, 83). It has been postulated that binding of
colloid molecules to the vWF–FVIII complex may accelerate
its urinary excretion, although to the authors’ knowledge there
are no data to support this (72, 84). While the secondary
coagulation effects of synthetic colloids are usually described
as affecting FVIII specifically, one study of HES administration
in dogs showed reductions in other coagulation factors (82).
There were concurrent reductions in the concentration of other
plasma proteins, along with increases in these proteins in the
lymph, leading to the hypothesis that the colloid osmotic effect
of synthetic colloids leads to extravascular relocation of proteins.
Additionally, an in vitro study suggested that AT activity is
maintained following hemodilution with HES, in contrast to the
decrease in activity seen with crystalloid hemodilution (85).
The strength of the fibrin clot is impaired by synthetic colloids.
Fibrin clots formed in the presence of HES or gelatin are
qualitatively different from those formed in undiluted blood, with
increased turbidity and mass/length ratio (86), and reduction
in clot density or weight (87–89). Images obtained by scanning
electron microscopy show less fibrin meshwork when blood
is diluted with either gelatin (Figure 1) or HES, compared
to dilution with 0.9% saline (88). Administration of HES to
rabbits caused impaired clot propagation and final clot strength
by inhibiting the interaction of factor XIII and fibrin, with
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FIGURE 1 | Scanning electron micrographs of whole blood diluted to 66% with 0.9% saline (A) or succinylated gelatin (B). Less fibrin meshwork is visible with gelatin
dilution. Reproduced with permission (88).
a secondary mechanism of inhibition of thrombin–fibrinogen
interaction (90). Studies in people (in vitro and in vivo) have also
demonstrated a reduction in FXIII, although this is in line with
a reduction in other coagulation factors (73, 91). Adding FXIII
and fibrinogen back into solution in an in vitro study partially
corrected coagulation impairment created by gelatin but not that
associated with HES (91). Also, infusing fibrinogen concentrate
after gelatin in a porcine hemorrhagic shockmodel improved clot
characteristics and reduced blood loss, compared to placebo (89).
Clots formed in the presence of HES are also susceptible to
accelerated fibrinolysis. Decreases in the urokinase-activated clot
lysis time, a measure of fibrinolysis, have been demonstrated
in vitro in human plasma mixed with HES and in blood
collected from healthy human volunteers administered HES
(92). Enhanced conversion of plasminogen to plasmin by
urokinase has been demonstrated in the presence of dextran
(93). Additionally, dilution of plasma with HES led to reduced
inhibition of plasmin by α2-antiplasmin (94).
Many of these mechanistic studies are several decades old
and were often conducted with a limited range of coagulation
assays. For example, whereas some studies have postulated a
specific effect against FVIII, most did not measure the activity
of other coagulation factors and so cannot exclude broader
effects. Additionally, some of the studies have contradictory
findings. These may relate to experimental technique, statistical
methods, sample size, or differences between the specific colloids
investigated. Often the types of colloid studied are no longer in
clinical use. Older colloids such as dextran and high MW HES
are believed to have greater effects on coagulation than modern
lowMWHES and gelatin. Thus, the exact mechanisms of colloid-
induced hypocoagulability and how much they vary between
different types of colloids are still unclear. More recent research,
including the bulk of the veterinary literature, has focused on the
effects of specific synthetic colloid fluids on clinically applicable
coagulation assays and clinical outcomes.
Hydroxyethyl Starch
The synthetic colloid most commonly administered in veterinary
medicine is HES, a synthetic polymer of amylopectin with
hydroxyethyl modification at the C2, C3, and C6 positions (60).
There are many HES products that differ in concentration,
average MW, molar substitution (average number of
hydroxyethyl modifications per glucose subunit), C2/C6
ratio (location of hydroxyethylation), the raw material from
which they are manufactured (maize or potato), and the carrier
solution (balanced crystalloid or 0.9% saline) (84, 95, 96). Higher
MW andmolar substitution delay degradation and are associated
with greater impairment of coagulation. Varieties of HES with
MW of >400 kDa are considered high MW, whereas 200–400
kDa is considered medium MW, and <200 kDa is considered
low MW. Despite the extensive literature on the effects of HES
in many species, this section will focus on the use in dogs, cats,
and horses.
In vitro studies have mostly demonstrated dose-dependent
impairment of coagulation following dilution of blood with
different types of HES, compared to crystalloid controls.
Common to these studies are measurements of platelet function
and viscoelastic tests of coagulation. In vitro dilution of canine
blood with high MW HES consistently causes hypocoagulability
beyond dilution, as measured by TEG (97, 98) and ROTEM
(27). Two of those studies also assessed platelet function and did
not show any effect beyond dilution on PCT (27, 98). However,
in another canine study, dilution with high MW HES showed
significant prolongation of PCT, compared to 0.9% saline dilution
(30). The only canine in vitro study of mediumMWHES showed
significant prolongation of PCT, compared to 0.9% saline (29).
Additional canine in vitro studies have used low MW HES,
with mixed results. Platelet dysfunction has been demonstrated
by changes in PCT (28) or a flow chamber model (99). Other
studies measuring PCT have failed to detect an effect beyond
dilution with low MW HES (27, 29, 98). Hypocoagulability
beyond dilutional effects has also been demonstrated for low
MW HES using TEG or ROTEM in three canine studies (27,
37, 98), but was not detected in a fourth (51). The only in vitro
study of HES dilution of equine blood showed that both high
and low MW HES caused significant platelet dysfunction and
hypocoagulability, as measured by PCT, TEG, Sonoclot, optical
platelet aggregometry, and activities of vWF and FVIII, with
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many changes in excess of the crystalloid controls (70). The
only feline in vitro study showed that blood diluted with HES
had ROTEM evidence of hypocoagulability beyond that of the
balanced isotonic crystalloid control (50). Most in vitro studies
did not report fibrinolysis data from viscoelastic testing.
A range of in vivo experiments have investigated changes in
platelet function and viscoelastic testing after HES administration
to healthy animals. High MW HES increased PCT in healthy
dogs when administered as a 20mL/kg bolus (41), compared to a
crystalloid control, or a constant rate infusion of 1 to 2 mL/kg
per hour, compared to baseline (100). Bolus administration
of 15 mL/kg of low MW HES to healthy dogs caused PCT
prolongation and ROTEM evidence of hypocoagulability beyond
dilution (53). However, a slow infusion over 2 h of 10 mL/kg
of low MW HES to healthy dogs did not cause any changes in
coagulation times or TEG parameters (101). Administration of 10
to 20mL/kg boluses of highMWHES to healthy horses decreased
vWF and FVIII activity (43, 44) and caused PCT prolongation
beyond the effects of dilution (44). In the latter study, low
MW HES caused similar alterations in coagulation, but of a
lower magnitude, and persisting for a shorter time (12 vs. 24 h).
Another study of healthy horses that were administered lowMW
HES showed some evidence of hypocoagulability on TEGwith 20
and 40mL/kg bolus doses (102). However, a different study found
no effects on TEG and only minor changes in PT and fibrinogen
concentration with a 10mL/kg bolus (103). The only study of the
coagulation effects of low MW HES in healthy foals found that
fibrinogen concentration was decreased with a 20mL/kg bolus,
compared to a balanced isotonic crystalloid control (104). Other
plasma coagulation assays did not show significant differences
to the balanced isotonic crystalloid control, but platelet function
and viscoelastic tests were not assessed. As with the in vitro
experiments, most of these studies did not assess fibrinolysis.
Additional in vivo experiments have been performed in
models of surgery, hemorrhage, and systemic inflammation. In
a canine model of orthopedic surgery, dogs administered a bolus
of 10 mL/kg high MWHES were compared to dogs administered
the same volume of balanced isotonic crystalloid (13). There
were no differences in plasma coagulation assays, platelet
aggregation, BMBT, or surgical hemorrhage. Two canine models
of hemorrhage showed evidence of hypocoagulability and platelet
dysfunction after the administration of 10 to 40mL/kg boluses
of high MW HES, compared to crystalloid, assessed using whole
blood and plasma clotting assays and bleeding times (105, 106).
Another early canine hemorrhage study showed hypocoagulable
TEG parameters after a total of 50mL/kg high MW HES, but
there was no crystalloid control (107). In a subsequent canine
hemorrhage model, high or mediumMWHES was administered
in combination with hypertonic crystalloid at a total dose of
6 mL/kg (108). Only a small prolongation of PT was detected,
compared to an autologous whole-blood control. More recently,
no difference in PCT was found when 20 mL/kg low MW HES
was compared to 80 mL/kg crystalloid for resuscitation in two
similar greyhound models of hemorrhagic shock (42, 81). The
more recent of these also included ROTEM analysis, with HES
administration prolonging the ExTEM CT significantly more
than the crystalloid control (81). In that study, the HES group
also had evidence of hypocoagulability when compared to a
group resuscitated with 20 mL/kg of fresh whole blood. As
the crystalloid group had fewer differences compared to fresh
whole blood, the study may have been underpowered to detect
all of the differences between HES and crystalloid resuscitation.
There was no evidence of hyperfibrinolysis. A different canine
model of less severe hemorrhage did not find any differences
in platelet count, BMBT, PT, aPTT, or ROTEM between groups
given low MW HES and crystalloid to cause hemodilution
to a hematocrit of 33% (109). A canine model of systemic
inflammation showed that administration of 40 mL/kg IV of low
MWHES was associated with TEG evidence of hypocoagulability
and a decrease in vWF concentration, changes that were greater
than the same volume of 0.9% saline (71). That study also
had a healthy control group with similar changes after HES
administration. Conversely, in a similar equine model, there
was no evidence of hypocoagulability when 10 mL/kg of high
MW HES was administered in combination with 5 mL/kg of
hypertonic crystalloid, compared to 15 or 60 mL/kg of 0.9%
saline (110).
There are very few veterinary clinical studies evaluating the
effects of HES on coagulation. In a prospective case series, 26
hypoalbuminemic dogs administered variable dosages of high
MW HES were monitored for clinical evidence of spontaneous
hemorrhage (111). Serial platelet count, PT, and aPTT were
measured in 18 of the dogs. Three dogs developed spontaneous
hemorrhage, and five had worsening of one or more coagulation
parameters. Given the lack of a control group, it is not possible
to determine whether these changes were due to HES by a
dilutional or non-dilutional mechanism or to the underlying
diseases. Historical case series describing the use of high MW
HES in combination with buffered isotonic crystalloid to treat
hypotension in 21 cats (112) and 16 dogs (113), both to
the authors’ knowledge only published in abstract form, did
not document any excessive bleeding (both dogs and cats) or
increases in activated clotting times (cats only). However, there
is little detail on how the treatment was administered or how
the animals were monitored. A prospective case series of 24
horses with colitis or surgical colic treated with a 10 mL/kg bolus
of medium MW HES showed significant prolongation in aPTT
postinfusion, compared to baseline, in the subgroup of horses
with large intestinal ileus (114). Given the lack of a control group,
it is unclear whether this was consistent with hemodilution
alone. There was no methodological detail on how horses were
monitored for clinical hemorrhage, but there was a statement
that no side effects were noted. A more recent prospective case
series in 20 hypoalbuminemic dogs administered low MW HES
as a constant rate infusion at 1 or 2 mL/kg per hour for 24 h did
not detect hypocoagulability with plasma coagulation assays or
ROTEM (115). A recent open-label clinical trial randomized 42
dogs with spontaneous hemoperitoneum to initial stabilization
with a bolus of either 10 mL/kg low MW HES or 30 mL/kg
balanced isotonic crystalloid (116). Immediately after infusion,
there was some ROTEM evidence of impaired clot initiation,
propagation, and strength in the HES group, compared to
the crystalloid group, with no evidence of hyperfibrinolysis.
Hemodynamic parameters were not different between groups
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immediately after infusion, but no subsequent monitoring for
hemorrhage was reported. A recent abstract evaluated banked
samples from a randomized blinded clinical trial comparing
bolus administration of low MW HES or balanced isotonic
crystalloid in 39 critically ill dogs (117). No differences between
fluid groups were detected in a broad panel of plasma coagulation
assays over the 24 h after fluid administration.
While many veterinary studies demonstrate laboratory
evidence of hypocoagulability in animals administered HES, data
on patient-centered endpoints are lacking. Many human clinical
trials have compared blood loss and transfusion requirement
between patients administered HES and crystalloid. Meta-
analyses of these generally suggest that HES is associated
with increased blood loss and transfusion requirement. The
latest Cochrane review documented an increased transfusion
requirement in critically ill patients treated with HES, compared
to crystalloid (118). Another meta-analysis suggested that
perioperative crystalloid therapy in patients undergoing major
non-cardiovascular surgery resulted in less blood loss, compared
to patients who received HES (119). Trauma guidelines
recommend avoiding HES because of the adverse effects on
hemostasis (120).
Gelatin
Gelatin-based colloid fluids have been in clinical use since the
1950s (121) and continue to maintain a presence among current
fluid choices. There are three different types of gelatin that have
been used over the years: oxypolygelatin, modified fluid gelatin
(succinylated gelatin), and urea-linked gelatin (polygeline). They
all stem from the hydrolysis of collagen but have undergone
different chemical processes in order to create a stable fluid
product containing molecules of an appropriate size (122). As
they have been reported to have various effects on coagulation,
it is important to note which type of gelatin is being referred
to when assessing any one study. Gelofusine R© (4% succinylated
gelatin) and Haemacell R© (urea-linked gelatin) have dominated
the literature in the last 20 years. Brand names are provided in
this section when relevant to either currently available products
or the diluent of the product.
Most of the evidence concerning gelatin’s effect on coagulation
stems from in vitro and in vivo research in people, with
few veterinary studies to draw upon. The dominant features
of coagulation perturbation include mild platelet dysfunction,
likely due to interference with vWF binding to collagen, and
interference with fibrin polymerization, causing more friable
blood clots. Similar to HES, in vitro studies demonstrate a
dose-dependent relationship on the effects of gelatin on platelet
function and viscoelastic testing, with changes evident beyond
∼30% dilution and more consistent at 50% or greater.
Gelatin products inhibit platelet aggregation in vitro when
ristocetin is used to initiate aggregation. This agonist binds to
vWF, which then stimulates the GP1b receptor on platelets.
Therefore, it is a test of either decreased vWF or dysfunctional
vWF. Impaired response to ristocetin seems to be an effect
particular to gelatin. In vitro studies using human blood have
shown that succinylated gelatin decreases platelet aggregation at
>40% dilution, compared to crystalloid dilution (78), although
some studies have shown no effect beyond dilutional (77). An in
vitro study in healthy people found a prolongation in PCTwith all
three types of gelatin that was similar to dilution with 0.9% saline
(64). Inhibition of ristocetin-induced platelet aggregation has
also been demonstrated ex vivo, when succinylated gelatin was
administered to healthy people (66), as well as those undergoing
either cardiac or orthopedic surgery (67, 73–75). A canine
hemorrhagic shock study found significantly longer PCT after
dogs were given 20 mL/kg of succinylated gelatin, compared to
the same dose of fresh whole blood or lowMWHES, or 80 mL/kg
of balanced crystalloid (81).
Compared to similar dilutions with crystalloid, in vitro
dilutions (10%, 20%, and 40%) of human whole blood with
succinylated gelatin cause a greater increase in CFT and greater
decrease in alpha angle and MCF on ROTEM, particularly at
a 40% dilution (77). Similar concentration-dependent changes
have been demonstrated with TEG (123, 124). Some differences
in clot rate, time to peak, and MA have also been demonstrated
with Sonoclot, with succinylated gelatin having a greater effect
compared to crystalloid (32, 33, 125). Studies comparing low
or medium MW HES and succinylated gelatin have shown that
HES causes a greater magnitude of change in some viscoelastic
test parameters, compared to gelatin, although the differences are
subtle or inconsistent (49, 124, 126–130).
Some studies have compared different types of gelatin to
each other, with the most consistent detrimental effects to
coagulation being shown for succinylated gelatin. Haemacell R©
showed minimal to no effects on Sonoclot testing in vitro,
whereas succinylated gelatin prolonged clot rate beyond the
effects of haemodilution (33). Haemacell R© has also been shown
to have some hypercoagulable effects on TEG, similar to the
addition of 0.9% saline to blood at a low dilution (20%) (131).
This mild hypercoagulable effect on TEG parameters was also
demonstrated in an earlier euvolemic hemodilution study in dogs
(107). Conversely, Haemacell R© decreases platelet aggregation
in response to a range of agonists, whereas Gelofusine R©
only causes decreased ristocetin-stimulated aggregation (78).
These differences between the fluids can be explained by
the presence of calcium within Haemacell R©, as the effects
of Gelofusine R© were similar when calcium was added in
vitro (78). Oxypolygelatin (Gelifundol R©) also appears to
cause less effect on viscoelastic measurements compared to
succinylated gelatin (Gelafusal R©) (123), although oxypolygelatin
does inhibit ristocetin-induced platelet aggregation, similar to
other gelatins (75). Finally, following in vitro activation of
platelets obtained from human whole blood diluted with various
gelatins, Haemacell R© increased the expression of integrin αIIbβ3
receptors, whereas oxypolygelatin (Gelifusin R©) had no effect, and
succinylated gelatin (Gelifundol R©) reduced expression (64).
There are few veterinary reports that document the effects
of gelatin on coagulation. Two canine studies assessed platelet
function; however, only one controlled for hemodilution (81,
132). This study found a longer PCT after an IV bolus of 20
mL/kg of succinylated gelatin, compared to the same dose of
either fresh whole blood or low MW HES, or 80 mL/kg of
balanced crystalloid (81). Using a hemorrhagic shock model
in dogs, one study showed a slightly increased PT and aPTT
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after 20 mL/kg of low MW HES given over 20min, compared
to a similar dose of succinylated gelatin (81). Another study
in healthy dogs showed no difference in PT or aPTT after 20
mL/kg of succinylated gelatin given IV over 2 h (101). An older
study that compared a range of synthetic colloids in a canine
euvolemic hemodilution model found effects on PT and aPTT to
be comparable between HES and Haemacell R© (107). No change
in PT and aPTT was found after 5 mL/kg of oxypolygelatin
in a second study, compared to baseline (132). Three of the
canine studies assessed viscoelastic coagulation (81, 101, 107),
with two studies showing more detrimental effects to the speed
and strength of clot formation following HES administration,
compared to similar doses of either Haemacell R© or succinylated
gelatin (81, 107).
Clinical outcomes assessed in human patients administered
a gelatin product include surgical blood loss, chest drain
output, and packed red blood cell transfusions. Chest drain
output is a standard measure of blood loss in cardiac surgery.
Other outcomes include organ failure scores, hospitalization
times, and mortality. Unfortunately, most of these studies have
small sample size, impairing their ability to identify definitive
differences between fluid types. The two recent large studies
with adequate sample size are not randomized trials, which may
have introduced bias into the results. Bearing this in mind,
one study in cardiac surgical patients found that perioperative
administration of succinylated gelatin was associated with a
higher chest drain output, higher grades of bleeding, and more
patients receiving red blood cell transfusions, compared to
the use of crystalloid (133). The second observational report
compared separate 2-year periods during which cardiac surgical
patients received a majority of succinylated gelatin, low MW
HES, or crystalloid in the perioperative period. In this study,
more patients received platelet transfusions in the gelatin group
than the other groups, and there was a higher risk of in-hospital
mortality in the gelatin group (134). Two limitations included
the potential bias of time and contamination of the gelatin
group with HES prime fluid during cardiopulmonary bypass.
Other smaller studies were not able to identify differences in
clinical outcomes between fluid types, either gelatin compared
to HES or crystalloid (73, 74, 76, 135–140). There are two
exceptions concerning studies in cardiac surgical patients. One
small randomized clinical trial (n = 15 per group) found that
patients receiving HES 200/0.5 received more blood products
than those receiving succinylated gelatin (137). This finding was
similar in another small randomized clinical trial (n = 55 per
group) comparing HES 200/0.5 to Haemacell R© (141). Given
the limitations of sample size and observational design, large
randomized controlled trials are needed to determine if gelatin
fluid products confer increased risk of clinical bleeding. The
number of subjects needed to answer this question may not be
feasible in veterinary medicine.
Albumin
The natural colloid albumin also has the potential to cause
hypocoagulability. The mechanisms may be similar to synthetic
colloids, with impairment of fibrin polymerization a leading
hypothesis. Rheologic analysis of samples following in vitro
dilution of blood from healthy volunteers with 4.5% albumin,
low MW HES, or gelatin showed measurements consistent
with weaker fibrin clots that were more permeable with less
branched polymerization for all three fluids (87). Furthermore,
hypocoagulability on ROTEM from in vitro albumin dilution can
be mostly reversed with the addition of fibrinogen concentrate
and factor XIII (142). Impairment of platelet function may
also occur, as in vitro addition of concentrated albumin to
human blood resulted in prolongation of PCT (143). That
study also showed ROTEM evidence of hypocoagulability with
increasing albumin concentration, despite a method that avoids
dilutional effects.
The hypocoagulability caused by albumin appears to be
greater than that caused by crystalloids, but less than that caused
by synthetic colloids. In vitro dilution of human blood with 4%
albumin led to greater ROTEM evidence of hypocoagulability
than 0.9% saline at a 40% dilution, but not 10 or 20%
(144). Another human in vitro study showed TEG evidence of
hypocoagulability, beyond dilutional effects, with both 30 and
60% dilutions of 5% albumin, but the changes were less than with
medium MW HES dilution (124). A similar in vitro comparison
showed less ROTEM hypocoagulability with albumin dilution
than with two low MWHES or succinylated gelatin fluids (128).
Human clinical studies have investigated the effects of 4
or 5% albumin administration on coagulation assays, blood
loss, and transfusion requirement. A substudy of the Saline
vs. Albumin Fluid Evaluation clinical trial showed that 4%
albumin administration was independently associated with aPTT
prolongation, but the effect size was small (145). In a clinical trial
of cardiac surgery patients randomized to receive LRS, low MW
HES, or 5% albumin, there was no difference between groups in
the primary outcome of postoperative chest drain output (17).
However, both colloid groups received more blood transfusions
than the crystalloid group, with no difference between HES and
albumin. Both colloids groups showed greater hypocoagulability
BOX 2 | Diagnostic modalities that can detect alterations in coagulation
function caused by uid administration.
Tests of platelet number and function
• Platelet count
• Bleeding times, such as buccal mucosal bleeding time
• Platelet function analyzer-100 (PFA-100) closure time
• Aggregometry
• Flow cytometry
• von Willebrand factor assays
Tests of plasma coagulation factor function
• Coagulation times (prothrombin time and activated partial thromboplastin
time)
• Fibrinogen concentration
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on ROTEM than crystalloid but with different patterns over
time: the HES group was the most hypocoagulable group at ICU
admission, whereas the albumin group was most hypocoagulable
group at 24 h postoperative. Similarly, in a clinical trial of
patients undergoing major surgery, patients randomized to 5%
albumin had significantly greater hypocoagulability of TEG
parameters than those randomized to LRS, with no difference
in blood loss or transfusion (146). There is currently no
published veterinary evidence for the effects of either human
or canine albumin administration on coagulation. However, as
the use of this product potentially increases over time, the
effects on coagulation will need to be considered. Additionally,
specific indications for albumin in veterinary patients (e.g.,
hypoalbuminemia due to enteral or renal protein loss) have
additional disease-related implications for altered coagulation
and should be studied directly.
In summary of the effects of colloids, synthetic colloids and
albumin cause a dose-dependent hypocoagulability equal to or
greater than that of an equivalent dose of isotonic crystalloids.
The evidence for differences between colloid types is not fully
elucidated but likely differs based on species and underlying
disease. Similar to crystalloids, caution should be used with large
doses of colloids and where there are other risk factors for
bleeding. Plasma transfusion may partially ameliorate colloid-
induced hypocoagulability. However, some adverse effects such
as platelet dysfunction may persist.
CONCLUSION
The bulk of the available evidence indicates that IV fluids,
when administered in clinically relevant doses, can cause dose-
dependent hypocoagulability. Synthetic colloids have a greater
potential for causing coagulopathy because of multiple non-
dilutional mechanisms. The exact differences between fluid
products and the clinical relevance of these effects remain an
area of investigation. The published body of literature covers a
broad range of species and diseases; targeted recommendations
for specific populations are not currently possible. Clinicians
should be mindful of the potential for hypocoagulability when
administering fluids.We recommend closelymonitoring relevant
coagulation assays (Box 2) and for evidence of hemorrhage
in patients receiving fluid therapy and pursuing goal-directed
patient-centered resuscitation. Vigilance is especially required
in patients with other risk factors for hemorrhage, those
receiving a large volume of fluid, or with the use of
synthetic colloids. Clinicians should strive for balance across
the use of different fluid types and consider replacement of
coagulation factors, via plasma transfusion, for bleeding patients
where appropriate.
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